In vitro and in vivo antibacterial activity of sitafloxacin

Japanese Journal of Chemotherapy

Volumn 56, Issue , 2008, Pages 1-17

  Kandau, Hiroko ^a   Kurosaka, Yuichi ^a   Fujikawa, Katsuko ^a   Chiba, Megumi ^a   Yamachika, Shinichiro ^a   Okumura, Ryo ^a   Kashimoto, Yoshinori ^a   Uoyama, Saori ^a   Hoshino, Kazuki ^a   Otani, Tsuyoshi ^a   Tanaka, Mayumi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

antibacterial activity; sitafloxacin

Indexed keywords

AMPICILLIN; CEFTAZIDIME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; IMIPENEM; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TOSUFLOXACIN; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CHLAMYDIACEAE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SIMULATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC DISEASE; URINARY TRACT INFECTION; WILD TYPE;

EID: 43449094348     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1995.56.Supplement1_1     Document Type: Article

References (28)

1. Yamaguchi K, Ohno A, the Levofloxacin Surveillance Group : Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates : a longitudinal analysis from 1994 to 2002. Di-agn Microbiol Infect Dis 2005; 52 : 135-43
2. Arslan H, Azap O K, Ergӫnül O, Timurkaynak F; Urinary Tract Infection Study Group : Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56 : 914-8
3. Muratani T, Matsumoto T : Urinary tract infection caused by fluoroquinolone-and cephem-resistant enter obacteriaceae. Int J Antimicrob Agents 2006; 28 (Suppl 1) : S 10-3
4. Jones M E, Sahm D F, Martin N, Scheuring S, Heisig P, Thornsberry C, et. al. : Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 19971998 respiratory season. Antimicrob Agents Chemother 2000; 44 : 462-6
5. Weigel L M, Anderson G J, Facklam R R, Tenover F C : Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45 : 3517-23
6. Canton R, Morosini M, Enright M C, Morrissey l : Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae : data from the global PRO-TEKT.surveillance programme. J Antimicrob Chemother 2003; 52 : 944-52
7. Lim S, Bast D, McGeer A, de Azavedo J, Low D E : Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae : redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9 : 833-7
8. Davies T A, Evangelista A, Pfleger S, Bush K, Sahm D F, Goldschmidt R : Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002; 46 : 119-24
9. Clinical and Laboratory Standards Institute : Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement M 100-S17. Clinical and Laboratory Standards Institute, Wayne, Pa, 2007
10. National Committee for Clinical Laboratory Standards : Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition, M 7-A 6. National Committee for Clinical Laboratory Standards, Wayne, Pa, 2003
11. Clinical and Laboratory Standards Institute : Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa, 2005
12. National Committee for Clinical Laboratory Standards : Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard-Sixth Edition, M11-A6. National Committee for Clinical Laboratory Standards. Wayne, Pa, 2004
13. Yamaguchi T, Hirakata Y, Izumikawa K, Miyazaki Y, Maesaki S, Tomono K, et. al. : In vitro activities of telithromycin(HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000; 44 : 1381-2
14. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M : Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995; 39 :1704
15. Kurosaka Y, Ishida Y, Yamamura E, Takase H, Otani T, Kumon H : A non-surgical rat model of foreign body-associated urinary tract infection with Pseudo-monas aeruginosa. Microbol Immunol 2001; 45 : 9-15
16. Kumon H : Pathogenesis and management of bacterial biofilms in the urinary tract. J Infect Chemother 1996; 2 : 18-28
17. Hooper D C : Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2 : 38-55
18. Piddock L J : Mechanisms of fluoroquinolone resistance : an update 1994-1998. Drugs 1999; 58 (Suppl 2) : S 11-8
19. Eliopoulos G M : Quinolone resistance mechanisms in pneumococci. Clin Infect Dis 2004; 38 (Suppl 4) : S 350-6
20. Heisig P : Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40 : 879-85
21. Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K : Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother 2000; 6 : 131-9
22. Akasaka T, Onodera Y, Tanaka M, Sato K : Cloning, expression, and enzymatic characterization of Pseu-domonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother 1999; 43 : 530-6
23. Hooper D C : Mechanisms of action of antimicrobials : focus on fluoroquinolones. Clin Infect Dis 2001; 32 (Suppl 1) : S 9-15
24. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T : Dual-targeting properties of 3-aminopyrrolidyl quinolones, DC-159a and sitaflox-acin, against DNA gyrase and topoisomerase IV : Contribution in reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008; in press
25. Lacy M K, Lu W, Xu X, Tessier P R, Nicolau D P, Quintiliani R : Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43 : 672-7
26. Andes D, Craig W A : Animal model pharmacokinetics and pharmacodynamics : a critical review. Int J Antimicrob Agents 2002; 19 : 261-8
27. Craig W A : Pharmacokinetic/pharmacodynamic parameters : rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 : 1-12
28. Craig W A : Does the dose matter? Clin Infect Dis 2001; 33 (Suppl 3) : S 233-729.